Pulmonary arterial hypertension in systemic lupus erythematosus;Hypertension artérielle pulmonaire associée au lupus systémique

Revue de Medecine Interne

Volumn 32, Issue 11, 2011, Pages 689-697

  Arnaud, L ^a,b   Agard, C ^b,c   Haroche, J ^a   Cacoub, P ^a,d,e   Piette, J C ^a   Amoura, Z ^a,b,d  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSERM   (France)

^c HÔTEL DIEU   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e CNRS   (France)

Author keywords

Pulmonary arterial hypertension; Pulmonary hypertension; Systemic lupus erythematosus

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; PHOSPHOLIPID ANTIBODY; VASODILATOR AGENT;

DYSPNEA; ECHOCARDIOGRAPHY; ENDOTHELIAL DYSFUNCTION; FIBROSIS; GOLD STANDARD; HEART CATHETERIZATION; HEART DISEASE; HUMAN; HYPOXIA; INTERSTITIAL LUNG DISEASE; PATHOGENESIS; PRACTICE GUIDELINE; PREVALENCE; PULMONARY HYPERTENSION; PULMONARY VENO-OCCLUSIVE DISEASE; SHORT SURVEY; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOEMBOLISM; VASCULAR DISEASE;

ALGORITHMS; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION, PULMONARY; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MODELS, BIOLOGICAL; PREVALENCE;

EID: 82455171951     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2011.01.002     Document Type: Short Survey

References (79)

1. Haute autorité de santé. Hypertension artérielle pulmonaire, protocole national de diagnostic et de soins pour une maladie rare. 1997.
2. Galie N., Hoeper M.M., Humbert M., Torbicki A., Vachiery J.L., Barbera J.A., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009, 34:1219-1263.
3. Simonneau G., Galie N., Rubin L.J., Langleben D., Seeger W., Domenighetti G., et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004, 43:5S-12S.
4. Hachulla E., Gressin V., Guillevin L., Carpentier P., Diot E., Sibilia J., et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a french nationwide prospective multicenter study. Arthritis Rheum 2005, 52:3792-3800.
5. Humbert M., Sitbon O., Chaouat A., Bertocchi M., Habib G., Gressin V., et al. Pulmonary arterial hypertension in france: results from a national registry. Am J Respir Crit Care Med 2006, 173:1023-1030.
6. Chung S.M., Lee C.K., Lee E.Y., Yoo B., Lee S.D., Moon H.B. Clinical aspects of pulmonary hypertension in patients with systemic lupus erythematosus and in patients with idiopathic pulmonary arterial hypertension. Clin Rheumatol 2006, 25:866-872.
7. Farzaneh-Far A., Roman M.J., Lockshin M.D., Devereux R.B., Paget S.A., Crow M.K., et al. Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus. Arthritis Rheum 2006, 54:3918-3925.
8. Foïs E. Prévalence de l'hypertension arterielle pulmonaire dans le lupus erythemateux systemique. Dépistage par échocardiographie. [thèse]. Paris: Université Paris 11; 2006.
9. Johnson S.R., Gladman D.D., Urowitz M.B., Ibanez D., Granton J.T. Pulmonary hypertension in systemic lupus. Lupus 2004, 13:506-509.
10. Li E.K., Tam L.S. Pulmonary hypertension in systemic lupus erythematosus: clinical association and survival in 18 patients. J Rheumatol 1999, 26:1923-1929.
11. Pan T.L., Thumboo J., Boey M.L. Primary and secondary pulmonary hypertension in systemic lupus erythematosus. Lupus 2000, 9:338-342.
12. Shen J.Y., Chen S.L., Wu Y.X., Tao R.Q., Gu Y.Y., Bao C.D., et al. Pulmonary hypertension in systemic lupus erythematosus. Rheumatol Int 1999, 18:147-151.
13. Simonson J.S., Schiller N.B., Petri M., Hellmann D.B. Pulmonary hypertension in systemic lupus erythematosus. J Rheumatol 1989, 16:918-925.
14. Tanaka E., Harigai M., Tanaka M., Kawaguchi Y., Hara M., Kamatani N. Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment. J Rheumatol 2002, 29:282-287.
15. Winslow T.M., Ossipov M.A., Fazio G.P., Simonson J.S., Redberg R.F., Schiller N.B. Five-year follow-up study of the prevalence and progression of pulmonary hypertension in systemic lupus erythematosus. Am Heart J 1995, 129:510-515.
16. Prabu A., Patel K., Yee C.S., Nightingale P., Situnayake R.D., Thickett D.R., et al. Prevalence and risk factors for pulmonary arterial hypertension in patients with lupus. Rheumatology (Oxford) 2009, 48:1506-1511.
17. Asherson R.A., Higenbottam T.W., Dinh Xuan A.T., Khamashta M.A., Hughes G.R. Pulmonary hypertension in a lupus clinic: experience with twenty-four patients. J Rheumatol 1990, 17:1292-1298.
18. Perez H.D., Kramer N. Pulmonary hypertension in systemic lupus erythematosus: report of four cases and review of the literature. Semin Arthritis Rheum 1981, 11:177-181.
19. Quismorio F.P., Sharma O., Koss M., Boylen T., Edmiston A.W., Thornton P.J., et al. Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus. Semin Arthritis Rheum 1984, 13:349-359.
20. Galie N., Torbicki A., Barst R., Dartevelle P., Haworth S., Higenbottam T., et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The task force on diagnosis and treatment of pulmonary arterial hypertension of the european society of cardiology. Eur Heart J 2004, 25:2243-2278.
21. Badui E., Garcia-Rubi D., Robles E., Jimenez J., Juan L., Deleze M., et al. Cardiovascular manifestations in systemic lupus erythematosus. Prospective study of 100 patients. Angiology 1985, 36:431-441.
22. Fauchier L., Goupille P., Babuty D., Marchal C., Valat J.P., Fauchier J.P., et al. Precapillary pulmonary arterial hypertension disclosing systemic lupus erythematosus. Arch Mal Coeur Vaiss 1996, 89:477-480.
23. Kishida Y., Kanai Y., Kuramochi S., Hosoda Y. Pulmonary venoocclusive disease in a patient with systemic lupus erythematosus. J Rheumatol 1993, 20:2161-2162.
24. Galie N., Manes A., Farahani K.V., Pelino F., Palazzini M., Negro L., et al. Pulmonary arterial hypertension associated to connective tissue diseases. Lupus 2005, 14:713-717.
25. Sanchez O., Sitbon O., Jais X., Simonneau G., Humbert M. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 2006, 130:182-189.
26. Pope J. An update in pulmonary hypertension in systemic lupus erythematosus - do we need to know about it?. Lupus 2008, 17:274-277.
27. Pietra G.G., Capron F., Stewart S., Leone O., Humbert M., Robbins I.M., et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 2004, 43:25S-32S.
28. Lee S.D., Shroyer K.R., Markham N.E., Cool C.D., Voelkel N.F., Tuder R.M. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest 1998, 101:927-934.
29. Yokoi T., Tomita Y., Fukaya M., Ichihara S., Kakudo K., Takahashi Y. Pulmonary hypertension associated with systemic lupus erythematosus: predominantly thrombotic arteriopathy accompanied by plexiform lesions. Arch Pathol Lab Med 1998, 122:467-470.
30. Fayemi A.O. Pulmonary vascular disease in systemic lupus erythematosus. Am J Clin Pathol 1976, 65:284-290.
31. Haupt H.M., Moore G.W., Hutchins G.M. The lung in systemic lupus erythematosus. Analysis of the pathologic changes in 120 patients. Am J Med 1981, 71:791-798.
32. Roncoroni A.J., Alvarez C., Molinas F. Plexogenic arteriopathy associated with pulmonary vasculitis in systemic lupus erythematosus. Respiration 1992, 59:52-56.
33. Dorfmuller P., Humbert M., Perros F., Sanchez O., Simonneau G., Muller K.M., et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol 2007, 38:893-902.
34. Yeo P.P., Sinniah R. Lupus cor pulmonale with electron microscope and immunofluroescent antibody studies. Ann Rheum Dis 1975, 34:457-460.
35. Tew M.B., Arnett F.C., Reveille J.D., Tan F.K. Mutations of bone morphogenetic protein receptor type ii are not found in patients with pulmonary hypertension and underlying connective tissue diseases. Arthritis Rheum 2002, 46:2829-2830.
36. Rich S., Dantzker D.R., Ayres S.M., Bergofsky E.H., Brundage B.H., Detre K.M., et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987, 107:216-223.
37. Gussin H.A., Ignat G.P., Varga J., Teodorescu M. Anti-topoisomerase i (anti-scl-70) antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 2001, 44:376-383.
38. Renaudineau Y., Dugue C., Dueymes M., Youinou P. Antiendothelial cell antibodies in systemic lupus erythematosus. Autoimmun Rev 2002, 1:365-372.
39. Yoshio T., Masuyama J., Sumiya M., Minota S., Kano S. Antiendothelial cell antibodies and their relation to pulmonary hypertension in systemic lupus erythematosus. J Rheumatol 1994, 21:2058-2063.
40. Bordron A., Dueymes M., Levy Y., Jamin C., Leroy J.P., Piette J.C., et al. The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis. J Clin Invest 1998, 101:2029-2035.
41. Karmochkine M., Cacoub P., Dorent R., Laroche P., Nataf P., Piette J.C., et al. High prevalence of antiphospholipid antibodies in precapillary pulmonary hypertension. J Rheumatol 1996, 23:286-290.
42. Wolf M., Boyer-Neumann C., Parent F., Eschwege V., Jaillet H., Meyer D., et al. Thrombotic risk factors in pulmonary hypertension. Eur Respir J 2000, 15:395-399.
43. Vianna J.L., Khamashta M.A., Ordi-Ros J., Font J., Cervera R., Lopez-Soto A., et al. Comparison of the primary and secondary antiphospholipid syndrome: a european multicenter study of 114 patients. Am J Med 1994, 96:3-9.
44. Espinosa G., Cervera R., Font J., Asherson R.A. The lung in the antiphospholipid syndrome. Ann Rheum Dis 2002, 61:195-198.
45. Houman M.H., Smiti-Khanfir M., Ben Ghorbell I., Miled M. Systemic lupus erythematosus in tunisia: demographic and clinical analysis of 100 patients. Lupus 2004, 13:204-211.
46. Kawamura N., Tsutsui H., Fukuyama K., Hayashidani S., Koike G., Egashira K., et al. Severe pulmonary hypertension in a patient with systemic lupus erythematosus and minimal lupus activity. Intern Med 2002, 41:109-112.
47. Orfanos S.E., Psevdi E., Stratigis N., Langleben D., Catravas J.D., Kyriakidis M., et al. Pulmonary capillary endothelial dysfunction in early systemic sclerosis. Arthritis Rheum 2001, 44:902-911.
48. Constans J., Dupuy R., Blann A.D., Resplandy F., Seigneur M., Renard M., et al. Anti-endothelial cell autoantibodies and soluble markers of endothelial cell dysfunction in systemic lupus erythematosus. J Rheumatol 2003, 30:1963-1966.
49. Hassoun P.M., Thappa V., Landman M.J., Fanburg B.L. Endothelin 1: mitogenic activity on pulmonary artery smooth muscle cells and release from hypoxic endothelial cells. Proc Soc Exp Biol Med 1992, 199:165-170.
50. Belaidi E., Godin-Ribuot D. Le système endothéline son implication dans le système cardiovasculaire. Rev Med Interne 2010, 31:792-794.
51. Yamane K., Miyauchi T., Suzuki N., Yuhara T., Akama T., Suzuki H., et al. Significance of plasma endothelin-1 levels in patients with systemic sclerosis. J Rheumatol 1992, 19:1566-1571.
52. Matsuda J., Tsukamoto M., Gohchi K., Saitoh N., Miyajima Y., Kazama M. Effect of total-body cold exposure on plasma concentrations of von willebrand factor, endothelin-1 and thrombomodulin in systemic lupus erythematosus patients with or without raynaud's phenomenon. Acta Haematol 1992, 88:189-193.
53. Nakamura T., Ebihara I., Tomino Y., Koide H. Effect of a specific endothelin a receptor antagonist on murine lupus nephritis. Kidney Int 1995, 47:481-489.
54. Yoshio T., Masuyama J., Mimori A., Takeda A., Minota S., Kano S. Endothelin-1 release from cultured endothelial cells induced by sera from patients with systemic lupus erythematosus. Ann Rheum Dis 1995, 54:361-365.
55. Atsumi T., Khamashta M.A., Haworth R.S., Brooks G., Amengual O., Ichikawa K., et al. Arterial disease and thrombosis in the antiphospholipid syndrome: a pathogenic role for endothelin 1. Arthritis Rheum 1998, 41:800-807.
56. Kim W.U., Min J.K., Lee S.H., Park S.H., Cho C.S., Kim H.Y. Causes of death in korean patients with systemic lupus erythematosus: a single center retrospective study. Clin Exp Rheumatol 1999, 17:539-545.
57. Dartevelle P., Fadel E., Mussot S., Chapelier A., Herve P., de Perrot M., et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2004, 23:637-648.
58. Rich S., Kaufmann E., Levy P.S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992, 327:76-81.
59. Sitbon O., Humbert M., Jais X., Ioos V., Hamid A.M., Provencher S., et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005, 111:3105-3111.
60. Barst R.J., Rubin L.J., Long W.A., McGoon M.D., Rich S., Badesch D.B., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The primary pulmonary hypertension study group. N Engl J Med 1996, 334:296-302.
61. Badesch D.B., Tapson V.F., McGoon M.D., Brundage B.H., Rubin L.J., Wigley F.M., et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000, 132:425-434.
62. Humbert M., Sanchez O., Fartoukh M., Jagot J.L., Le Gall C., Sitbon O., et al. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study. Eur Respir J 1999, 13:1351-1356.
63. Robbins I.M., Gaine S.P., Schilz R., Tapson V.F., Rubin L.J., Loyd J.E. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest 2000, 117:14-18.
64. Kong K.O., Badsha H., Thumboo J., Chng H.H. Intermittent epoprostenol infusions in systemic lupus erythematosus associated pulmonary hypertension-a series of three cases. Ann Acad Med Singapore 2003, 32:118-121.
65. Matsukawa Y., Igei K., Nozaki T., Ohki T., Shimizu T., Kitamura N., et al. Low-dose epoprostenol improved pulmonary hypertension in a patient with systemic lupus erythematosus. Clin Rheumatol 2007, 26:582-583.
66. Sitbon O., Humbert M., Simonneau G. Treatment for pulmonary arterial hypertension under the new french hospital financing system Recommendations of the pulmonary vascular diseases working group of the French society of pulmonary medicine. Presse Med 2005, 34:1456-1464.
67. Oudiz R.J., Schilz R.J., Barst R.J., Galie N., Rich S., Rubin L.J., et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 2004, 126:420-427.
68. Olschewski H., Simonneau G., Galie N., Higenbottam T., Naeije R., Rubin L.J., et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002, 347:322-329.
69. Denton C.P., Humbert M., Rubin L., Black C.M. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: A subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 2006, 65:1336-1340.
70. Marotta H., Montisci R., Tiso F., Pontarollo S., Rizzo M., Tona F., et al. Two-years therapy with bosentan of pulmonary arterial hypertension related to connective tissue diseases. Reumatismo 2007, 59:299-303.
71. Mok M.Y., Tsang P.L., Lam Y.M., Lo Y., Wong W.S., Lau C.S. Bosentan use in systemic lupus erythematosus patients with pulmonary arterial hypertension. Lupus 2007, 16:279-285.
72. Girgis R.E., Frost A.E., Hill N.S., Horn E.M., Langleben D., McLaughlin V.V., et al. Selective endothelin a receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. Ann Rheum Dis 2007, 66:1467-1472.
73. Galie N., Badesch D., Oudiz R., Simonneau G., McGoon M.D., Keogh A.M., et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005, 46:529-535.
74. Galie N., Olschewski H., Oudiz R.J., Torres F., Frost A., Ghofrani H.A., et al. Ambrisentan for the treatment of pulmonary arterial hypertension: Results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (aries) study 1 and 2. Circulation 2008, 117:3010-3019.
75. Oudiz R.J., Galie N., Olschewski H., Torres F., Frost A., Ghofrani H.A., et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol 2009, 54:1971-1981.
76. Badesch D.B., Hill N.S., Burgess G., Rubin L.J., Barst R.J., Galie N., et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol 2007, 34:2417-2422.
77. Galie N., Brundage B.H., Ghofrani H.A., Oudiz R.J., Simonneau G., Safdar Z., et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009, 119:2894-2903.
78. Gonzalez-Lopez L., Cardona-Munoz E.G., Celis A., Garcia-de la Torre I., Orozco-Barocio G., Salazar-Paramo M., et al. Therapy with intermittent pulse cyclophosphamide for pulmonary hypertension associated with systemic lupus erythematosus. Lupus 2004, 13:105-112.
79. Levy R.D., Guerraty A.J., Yacoub M.H., Loertscher R. Prolonged survival after heart-lung transplantation in systemic lupus erythematosus. Chest 1993, 104:1903-1905.